» Articles » PMID: 16224536

Protein Phosphatase 2A is a Negative Regulator of IL-2 Production in Patients with Systemic Lupus Erythematosus

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2005 Oct 15
PMID 16224536
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Decreased IL-2 production in systemic lupus erythematosus (SLE) represents a central component of the disease immunopathology. We report that the message, protein, and enzymatic activity of the catalytic subunit of protein phosphatase 2A (PP2Ac), but not PP1, are increased in patients with SLE regardless of disease activity and treatment and in a disease-specific manner. Treatment of SLE T cells with PP2Ac-siRNA decreased the protein levels and activity of PP2Ac in a specific manner and increased the levels of phosphorylated cAMP response element-binding protein and its binding to the IL2 and c-fos promoters, as well as increased activator protein 1 activity, causing normalization of IL-2 production. Our data document increased activity of PP2A as a novel SLE disease-specific abnormality and define a distinct mechanism whereby it represses IL-2 production. We propose the use of PP2Ac-siRNA as a novel tool to correct T cell IL-2 production in SLE patients.

Citing Articles

Protein phosphatases in systemic autoimmunity.

Pan W, Tsokos M, Li W, Tsokos G Immunometabolism (Cobham). 2025; 7(1):e00056.

PMID: 39944077 PMC: 11812671. DOI: 10.1097/IN9.0000000000000056.


Exploring genetic associations in systemic lupus erythematosus through Mendelian randomization: implications for novel biomarkers and therapeutic targets.

Liu Q, Liu Y, Feng H, Zhao L, Wan T Clin Rheumatol. 2024; 44(1):193-205.

PMID: 39126578 DOI: 10.1007/s10067-024-07094-0.


PP2A catalytic subunit alpha is critically required for CD8 T-cell homeostasis and antibacterial responses.

Zhou X, Li M, Ai M, Li Y, Zhu X, Hansen M Eur J Immunol. 2024; 54(10):e2451080.

PMID: 39072720 PMC: 11550909. DOI: 10.1002/eji.202451080.


The PP2A regulatory subunit PPP2R2A controls NAD biosynthesis to regulate T cell subset differentiation in systemic autoimmunity.

Pan W, Tsokos M, Scherlinger M, Li W, Tsokos G Cell Rep. 2024; 43(7):114379.

PMID: 38889006 PMC: 11414414. DOI: 10.1016/j.celrep.2024.114379.


Identification of key genes as potential diagnostic and therapeutic targets for comorbidity of myasthenia gravis and COVID-19.

Huang L, Zuo Y, Yang H, He X, Zhang L Front Neurol. 2024; 14:1334131.

PMID: 38384322 PMC: 10879883. DOI: 10.3389/fneur.2023.1334131.


References
1.
Evans D, Myles T, Hofsteenge J, Hemmings B . Functional expression of human PP2Ac in yeast permits the identification of novel C-terminal and dominant-negative mutant forms. J Biol Chem. 1999; 274(34):24038-46. DOI: 10.1074/jbc.274.34.24038. View

2.
Di Cristofano A, Kotsi P, Peng Y, Cordon-Cardo C, Elkon K, Pandolfi P . Impaired Fas response and autoimmunity in Pten+/- mice. Science. 1999; 285(5436):2122-5. DOI: 10.1126/science.285.5436.2122. View

3.
Seminario M, Precht P, Bunnell S, Warren S, Morris C, Taub D . PTEN permits acute increases in D3-phosphoinositide levels following TCR stimulation but inhibits distal signaling events by reducing the basal activity of Akt. Eur J Immunol. 2004; 34(11):3165-75. DOI: 10.1002/eji.200425206. View

4.
Roach S, Lee S, Schorey J . Differential activation of the transcription factor cyclic AMP response element binding protein (CREB) in macrophages following infection with pathogenic and nonpathogenic mycobacteria and role for CREB in tumor necrosis factor alpha production. Infect Immun. 2004; 73(1):514-22. PMC: 538945. DOI: 10.1128/IAI.73.1.514-522.2005. View

5.
Juang Y, Wang Y, Solomou E, Li Y, Mawrin C, Tenbrock K . Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest. 2005; 115(4):996-1005. PMC: 1070410. DOI: 10.1172/JCI22854. View